Summit Therapeutics Income Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar '26 Mar 31, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Selling, General & Admin	-603.76	-556.75	-60.21	-29.26	-26.74	-23.61
Research & Development	-619.03	-537.67	-135.77	461.44	-52	-85.35
Other Operating Expenses	-	-	-	-	-5.95	-20.97
Total Operating Expenses	-1,223	-1,094	-195.98	432.18	-84.69	-129.93
Operating Income	1,223	1,094	195.98	-432.18	-72.09	-86.19
Interest Expense	-	-	-8.69	-16.46	-4.4	-
Other Non-Operating Income (Expense)	-172.74	14.84	13.37	11.18	-2.29	-2.42
Total Non-Operating Income (Expense)	-172.74	14.84	4.68	-5.28	-6.69	-2.42
Pretax Income	1,050	1,109	200.67	-437.46	-78.78	-88.6
Net Income	-1,005	-1,080	-221.32	-614.93	-78.78	-88.6
Net Income to Common	-1,005	-1,080	-221.32	-614.93	-78.78	-88.6
Shares Outstanding (Basic)	757	748	719	620	193	132
Shares Outstanding (Diluted)	757	748	719	620	193	132
Shares Change (YoY)	4.05%	4.06%	15.96%	220.50%	46.78%	89.45%
EPS (Basic)	-1.60	-1.44	-0.31	-0.99	-0.41	-0.67
EPS (Diluted)	-1.60	-1.44	-0.31	-0.99	-0.41	-0.67
Shares Outstanding	776.02	775.37	737.63	701.66	211.09	98.04
Free Cash Flow	-384.53	-323.59	-142.25	-76.89	-42.21	-72.89
Free Cash Flow Per Share	-0.51	-0.43	-0.20	-0.12	-0.22	-0.55
EBITDA	1,223	1,095	196.07	-431.98	-70.83	-83.73
EBIT	1,223	1,094	195.98	-432.18	-72.09	-86.19

Updated May 1, 2026. Data Source: Fiscal.ai. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q